L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Friendship Hospital
About this trial
The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.
Eligibility criteria
Qualifiers
Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.
EBV-DNA in peripheral blood > 1000 copies/ml or EBER detected in tissue specimens.
Age 18~65，gender is not limited.
Estimated survival time ≥ 1 month.
Disqualifiers
Heart function above grade II (NYHA).
Severe myocardial injury：TNT、TNI、CK-MB > 3 ULN.
Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above 750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced cardiovascular disease.
Pregnancy or lactating Women.
Trial design
Treatments tested in this trial
- L-DEP and PD-1 antibody
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov